DOI: 10.3724/SP.J.1008.2008.00461

Academic Journal of Second Military Medical University (第二军医大学学报) 2008/28:4 PP.461-462

Application of sirolimus in patients with renal injury after liver transplantation


Key words:

ReleaseDate:2014-07-21 14:10:25

[1]de Mattos A M,Olyaei A J,Bennett W M.Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future[J].Am J Kidney Dis,2000,35:333-346.

[2]Morales J M,Wramner L,Kreis H,Durand D, Campistol J M, Andres A, et a1.Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients[J].Am J Transplant,2002,2:436-442.

[3]Rimola A,Gavaler J S,Schade R R,el-Lankany S, Starzl T E, Van Thiel D H.Effects of renal impairment on liver transplantation[J].Gastroenterology,1987,93:148-156.

[4]Soliman G A.The mammalian target of rapamycin signaling network and gene regulation[J].Curr Opin Lipidol,2005,16:317-323.

[5]Watson C J,Friend P J,Jamieson N V,Frick T W,Alexander G,Gimson A E,et al.Sirolimus: a potent new immunosuppressant for liver transplantation[J].Transplantation,1999,67:505-509.

[6]Ciancio G,Burke G W,Gaynor J J,Mattiazzi A,Roth D,Kupin W,et a1.A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. Ⅱ. Survival,function,and protocol compliance at 1 year[J].Transplantation,2004,77:252-258.

[7]Golling M,Becker T,Broelsch C,Candinas D,Faust D,Fischer L,et al.Consensus-recommendations for sirolimus in liver transplantation[J].Z Gastroenterol,2004,42:1333-1340.

[8]Watson C J,Gimson A E,Alexander G J,Allison M E,Gibbs P,Smith J C,et al.A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function[J].Liver Transpl,2007,13:1694-1702.

[9]Emiroglu R,Ayvaz I,Moray G,Karakayali H,Haberal M. Tacrolimus-related neurologic and renal complications in liver transplantation: A single-center experience[J].Transplantation Proc,2006,38:619-621.

[10]Morard I,Dumortier J,Spahr L,Hadengue A,Majno P,Morel P,et al.Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients[J].Liver Transpl,2007,13:658-664.

[11]Baboolal K.A phase Ⅲ prospective,randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients[J].Transplantation,2003,75:1404-1408.

[12]Kreis H,Cisterne J M,Land W,Wramner L,Squifflet J P,Abramowicz D,et al.Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients[J].Transplantation,2000,69:1252-1260.

[13]Fung J,Kelly D,Kadry Z,Patel-Tom K,Eghtesad B.Immunosuppression in liver transplantation: beyond calcineurin inhibitors[J].Liver Transpl,2005:11:267-280.